Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177182 | 0.85 | POLB (0.39) | ROCK1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL21189725 | 0.84 | KMT2A (0.50) | ROCK1MEN1KMT2AALDH1A1HTT | |
| SCHEMBL14880763 | 0.82 | KMT2A (0.40) | ROCK1MEN1KMT2ACNR2ALDH1A1 | |
| SCHEMBL21177377 | 0.78 | RAB9A (0.42) | ROCK1MEN1KMT2ACNR2ALDH1A1 | |
| SCHEMBL21177379 | 0.78 | RAB9A (0.42) | ROCK1MEN1KMT2ACNR2ALDH1A1 | |
| SCHEMBL21177543 | 0.78 | SMN1; SMN2 (0.44) | MEN1KMT2AALDH1A1HTTL3MBTL3 | |
| SCHEMBL2798855 | 0.74 | HPGD (0.46) | ROCK1MEN1KMT2ACNR2ALDH1A1 | |
| SCHEMBL2720778 | 0.74 | LIPG (0.45) | ROCK1HIF1ALIPGP4HB | |
| SCHEMBL17464370 | 0.74 | LIPG (0.41) | ROCK1HIF1ALIPGP4HB | |
| SCHEMBL32678806 | 0.74 | LIPG (0.45) | ROCK1HIF1ALIPGP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-05-16 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-12-16 | — | — | US | disclosed |
| EP-3740489-A1 | PI4KIIIBETA INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-11-25 | — | — | EP | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141694-A1 | PI4KIIIBETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124394-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | ROCK1 86/4885MEN1 3572/4885KMT2A 1239/4885 |
| US-11649238-B2 | Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors | PI4K2A, PI4K2B, PI4KA | ROCK1 660/4885MEN1 4344/4885KMT2A 1679/4885 |
| US-20240336618-A1 | PI4KIIIBETA INHIBITORS | PI4KB, PI4K2B, PI4K2A | ROCK1 97/4885MEN1 3563/4885KMT2A 1237/4885 |
| US-20210387988-A1 | PI4KIIIbeta Inhibitors | PI4KB, PI4K2B, PI4K2A | ROCK1 97/4885MEN1 3563/4885KMT2A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.